Vimarsana
Biggest News Aggregation in the World

Mark Marmur News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Marmur. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Marmur Today - Breaking & Trending Today

Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call Transcript - Vimarsana News

Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call Transcript

Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call Transcript May 1, 2024 Amarin Corporation plc misses on earnings expectations. Reported EPS is $-0.01 EPS, expectations were $-0.0075. AMRN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome […]

Source: yahoo.com
Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript - Vimarsana News

Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript

AMRN earnings call for the period ending March 31, 2024.

Source: yahoo.com
Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event - Vimarsana News

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect PatientsDUBLIN, Ireland and...

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 - Vimarsana News

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of ActionDUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 -- Amarin Corporation plc today highlighted three data...

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups - Vimarsana News

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp, LDL-C Levels -- -- Lp Results Published Simultaneously in the Journal of the American...